Drug
GSK3640254 clinical trials
Also written GSK3640254.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
14 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Dolutegravir (2) · Darunavir/Ritonavir (1) · Etravirine (1) · Caffeine (1) · Metoprolol (1) · Montelukast (1) · Flurbiprofen (1) · Omeprazole (1)
Studies
Open first, then newest update. How each study uses GSK3640254 is read from its arms, and is right about nine times in ten.
Testing it · 14
- Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)CompletedPhase 1ViiV HealthcareNCT04630002Written as GSK3640254
- A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive AdultsTerminatedPhase 2ViiV HealthcareNCT04493216Written as GSK3640254
- A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy ParticipantsCompletedPhase 1ViiV HealthcareNCT04857892Written as GSK3640254
- Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy AdultsCompletedPhase 1ViiV HealthcareNCT04425902Written as GSK3640254 200 mg
- A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive AdultsTerminatedPhase 2ViiV HealthcareNCT04900038Written as GSK3640254
- Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254CompletedPhase 1ViiV HealthcareNCT04507321Written as GSK3640254 Oral tablet
- GSK3640254 First Time in Human (FTIH) Study in Healthy VolunteersCompletedPhase 1ViiV HealthcareNCT03231943Written as GSK3640254
- A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy ParticipantsCompletedPhase 1ViiV HealthcareNCT04263142Written as GSK3640254 Tablet
- A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive AdultsCompletedPhase 2ViiV HealthcareNCT03784079Written as GSK3640254
- Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral ContraceptiveCompletedPhase 1ViiV HealthcareNCT03984825Written as GSK3640254
- A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy ParticipantsTerminatedPhase 1ViiV HealthcareNCT04128293Written as GSK3640254 Tablet
- Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/EmtricitabineCompletedPhase 1ViiV HealthcareNCT03836729Written as GSK3640254
- Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)CompletedPhase 1ViiV HealthcareNCT03816696Written as GSK3640254
- A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254CompletedPhase 1ViiV HealthcareNCT03575962Written as GSK3640254 bis-hydrochloride salt capsule